## Agent-Based Simulation for Neovascular AMD Treatment Planning

Optimizing Anti-VEGF Therapy Protocols in the NHS

Luke Herbert Consultant Ophthalmologist

24th June 2025

Surrey and Sussex Healthcare NHS Trust

## Acknowledgments

- · Health Service Modelling Associates (HSMA) team
- · Finance Director and IT Director
- · NHS England Pharmacy & Clinical Support Team

Understanding Neovascular AMD

### What is Neovascular AMD (NAMD)?

- · Leading cause of central vision loss
- Cannot read or recognize faces
- · Leads to legal blindness if untreated
- Affects quality of life severely

6/96	NCKZ0	ETDRS 20
6/48	NCKZ0	ETDRS 35
6/24	NCKZO	ETDRS 55
6/12 6/6	90920 mm	ETDRS 70 ETDRS 85



## The Biology Behind NAMD

#### **Disease Process:**

- Aging eye environment
- Increased VEGF (Vascular Endothelial Growth Factor)
- · Abnormal blood vessel growth
- · Leakage, fibrosis, and bleeding

# **VEGF?**VEGF is like fertiliser for blood vessels. Anti-VEGF is something that removes the fertiliser.

As VEGF keeps being made we have to keep removing it.

## Revolutionary Treatment: Anti-VEGF Therapy

#### How it works:

- · Antibodies or similar molecules bind to VEGF
- Remove growth factor from eye
- Stop abnormal vessel growth

#### The Challenge:

- · Molecules cleared over time
- · Requires repeated injections
- · Optimal frequency unknown



## Real-World Treatment Challenges

#### Why Patients Stop Treatment

- Mortality: Elderly population (average age 80+)
- Frailty: Too unwell to attend monthly appointments
- Treatment failure: Vision deteriorates despite therapy
- NHS capacity: Limited appointment availability

#### **Discontinuation Rates**

- Year 1: 10-15% stop treatment
- Year 2: Additional 10-15%
- By Year 5: Only 50-60% still on treatment

Critical Question: How do we optimise treatment for those who remain?

The Cost Challenge

#### **NHS Annual Treatment Costs**


Treatment Area	Annual NHS Spend	Annual Patient Numbers
Wet AMD (Anti-VEGF) Cataract Surgery	£600-800 million £320-480 million	40,000 new, 200,000 continuing 400,000
Hip Replacement	£500-700 million	100,000

#### Cost per QALY

- · Cataract surgery: £1,964 per QALY (exceptional value)
- · Hip replacement: £2,128 per QALY (strong value)
- Wet AMD: £58,047 per QALY (3x NICE threshold)

## Current Anti-VEGF Drug Costs (2024 list prices)

- · Aflibercept (Eylea): £816 a dose, generic soon maybe £400
- · Patients need 7-10 injections year 1, then 4-6/year ongoing



## The Need for Modeling

#### **Current Challenges:**

- · Treatment controversies
- · Limited real-world data
- Complex patient pathways
- Resource constraints

#### Modeling Benefits:

- Explore treatment strategies
- · Clarify outcome measures
- · Predict resource needs
- · Evidence-based decisions

## **Two Modeling Approaches**

#### Simple Approach (NHS England):

- Excel spreadsheet
- "Best guess" parameters
- Average patient behavior
- Quick but limited insights

#### Our Approach (Agent-Based):

- Individual patient simulation
- Build from known parameters
- · Probabilistic events
- Rich, detailed insights



## Real-World Complexity in Our Simulation

## simple Models Assume:

- · All patients start with same vision
- Perfect treatment adherence
- No appointment delays
- Uniform response to treatment

#### Why This Matters

- Captures NHS capacity constraints
- Models actual patient populations
- · Predicts realistic outcomes
- Enables better resource planning

#### **Our Simulation Includes:**


- Vision distribution at baseline
- Real discontinuation patterns
- Treatment gaps and delays
- Individual patient trajectories

Result: Evidence-based insights, not theoretical averages



## **Application Architecture**

#### Four Key Modules:



Next: Live demonstration of the application

#### Live Demonstration

## [Switch to Screen Recording]

#### Demonstration includes:

- Loading treatment protocols
- · Running 1000-patient simulation
- Exploring patient journeys
- Visualizing population outcomes
- Comparing different protocols

Key Insights

#### What We've Learned

#### Model Reveals:

- Treatment pattern impacts
- Resource utilization peaks
- · Patient outcome distributions
- Protocol efficiency metrics

#### **Enables:**

- · Evidence-based protocols
- Capacity planning
- Cost-effectiveness analysis
- Commissioning decisions

#### **Future Development**

Cost calculator module in development for full economic analysis

## Questions?

#### Contact:

your.email@nhs.net

Acknowledgments:

HSMA Team | NHS England | Trust Leadership